[go: up one dir, main page]

AU2003232941A1 - N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them - Google Patents

N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them

Info

Publication number
AU2003232941A1
AU2003232941A1 AU2003232941A AU2003232941A AU2003232941A1 AU 2003232941 A1 AU2003232941 A1 AU 2003232941A1 AU 2003232941 A AU2003232941 A AU 2003232941A AU 2003232941 A AU2003232941 A AU 2003232941A AU 2003232941 A1 AU2003232941 A1 AU 2003232941A1
Authority
AU
Australia
Prior art keywords
mercaptoacyl
phenyalanine
derivatives
preparation
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003232941A
Inventor
Anthony William James Cooper
Jacqueline Elizabeth Mordaunt
Simon Peace
Paul William Smith
Steven Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0213119A external-priority patent/GB0213119D0/en
Priority claimed from GB0216856A external-priority patent/GB0216856D0/en
Priority claimed from GB0220875A external-priority patent/GB0220875D0/en
Priority claimed from GB0302543A external-priority patent/GB0302543D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003232941A1 publication Critical patent/AU2003232941A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003232941A 2002-06-07 2003-06-05 N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them Abandoned AU2003232941A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0213119A GB0213119D0 (en) 2002-06-07 2002-06-07 Compounds
GB0213119.1 2002-06-07
GB0216856.5 2002-07-01
GB0216856A GB0216856D0 (en) 2002-07-19 2002-07-19 Compounds
GB0220875A GB0220875D0 (en) 2002-09-09 2002-09-09 Compounds
GB0220875.9 2002-09-09
GB0302543.4 2003-02-04
GB0302543A GB0302543D0 (en) 2003-02-04 2003-02-04 Compounds
PCT/GB2003/002446 WO2003104200A1 (en) 2002-06-07 2003-06-05 N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
AU2003232941A1 true AU2003232941A1 (en) 2003-12-22

Family

ID=29740912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003232941A Abandoned AU2003232941A1 (en) 2002-06-07 2003-06-05 N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them

Country Status (4)

Country Link
AR (1) AR040441A1 (en)
AU (1) AU2003232941A1 (en)
TW (1) TW200407310A (en)
WO (1) WO2003104200A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094897A2 (en) 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
EP1984344B1 (en) 2005-12-29 2012-09-26 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
ES2656798T3 (en) 2007-08-24 2018-02-28 Lexicon Pharmaceuticals, Inc. Methods of preparing compounds based on 4-phenyl-6- (2,2,2-trifluoro-1-phenylethoxy) pyrimidine
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
JP2016527249A (en) 2013-07-25 2016-09-08 ノバルティス アーゲー Synthetic apelin polypeptide bioconjugates
AU2014293386B2 (en) 2013-07-25 2016-11-17 Novartis Ag Cyclic polypeptides for the treatment of heart failure
BR112017014194A2 (en) 2015-01-23 2018-01-09 Novartis Ag synthetic apelin fatty acid conjugates with improved half life
EP3887388A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (en) 2018-11-27 2020-06-30 Novartis Ag CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
TW202333563A (en) 2021-11-12 2023-09-01 瑞士商諾華公司 Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760241A (en) * 1995-12-28 1998-06-02 Zambon Group S.P.A. Thiol derivatives with metallopeptidase inhibitory activity
IT1277737B1 (en) * 1995-12-28 1997-11-12 Zambon Spa TIOLIC DERIVATIVES FOR METALLOPEPTIDASE INHIBITIVE ACTIVITY

Also Published As

Publication number Publication date
TW200407310A (en) 2004-05-16
AR040441A1 (en) 2005-04-06
WO2003104200A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
AU2003239302A1 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
HUP0402161A3 (en) Nicotin-or isonicotin benzothiazole derivatives, process for their preparation and pharmaceutical compositions containing them
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
EP1706412A4 (en) Novel pyridine derivatives, a process for their preparation and a pharmaceutical composition containing the same
AU2002233463A1 (en) Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use
HUP0402225A3 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
IL173195A0 (en) Cyclovinylazoline derivatives, their preparation and pharmaceutical compositions containing them
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
AU2003297199A1 (en) Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
AU2003232941A1 (en) N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them
AU2003202719A1 (en) Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.
AU2003251695A1 (en) Novel thiophene derivatives, preparation method thereof and pharmaceutical compositions containing same
AU2003231920A1 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
AU2003286944A1 (en) Crude drug compositions and the process for preparing them
IL166098A0 (en) 3-guanindinocarbonyl-1-heteroaryl-indole derivatives preparation process their use as medicaments and pharmaceutical compositions comprising them
AU2002313065A1 (en) Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
AU2002306687A1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
SI1241169T1 (en) Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them
SI1245565T1 (en) Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them
AU2003267848A1 (en) Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same
AU2003274676A1 (en) Antimicrobial oxazolidinones, process of their preparation, and pharmaceutical compositions containing them
HUP0401038A3 (en) Piperazinylcarbonylquinolines and -isoquinolines, process for their preparation and pharmaceutical compositions containing them
AU2003229863A1 (en) Porphyrin derivatives, method for the production thereof, pharmaceutical compositions and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase